Results 161 to 170 of about 113,598 (259)

Hydrochlorides, hydrates, hydronitrate, and an unanticipated hydrolysis product of famotidine

open access: yesActa Crystallographica Section C, Volume 82, Issue 5, Page 241-249, May 2026.
The structures of a new polymorph of famotidine hydrochloride, a famotidine hydrochloride hydrate, a new hydronitrate salt of famotidine, and an unexpected hydrolyzed complex of famotidine are reported. The famotidine hydrochloride hydrate and the hydrolyzed famotidine hydrochloride have Z′ values of 2 and 4, respectively.This article contributes to ...
MacKenzie C. Weaver   +2 more
wiley   +1 more source

Advances in Wine Yeast Autolysis: Biochemical and Molecular Mechanisms, and the Release of Organic Compounds in White and Sparkling Wines—An Updated Review

open access: yesComprehensive Reviews in Food Science and Food Safety, Volume 25, Issue 3, May 2026.
ABSTRACT Wine yeasts play a central role in alcoholic fermentation and significantly contribute to the sensory attributes of wines through cellular autolysis during lees aging (sur lie), especially in white wines. This process releases organic compounds that alter the wine's chemical and sensory profile.
José Ricardo Machado dos Santos   +1 more
wiley   +1 more source

Qualitative and semi‐quantitative primary and secondary transfer of metal traces by human touch detected using SEM–EDS technique: A pilot study

open access: yesJournal of Forensic Sciences, Volume 71, Issue 3, Page 1420-1427, May 2026.
Abstract The present pilot study aimed to assess the transfer of metal residues on fingertips after contact with different items (primary transfer) as well as the transfer of metal residues by human fingertips from metal objects to different surfaces (secondary transfer).
Barbara Bertoglio   +5 more
wiley   +1 more source

Divergence in μ and δ opioid receptor pharmacology in neurons and antinociceptive efficacy in neuropathic pain: Insights from MP135 and CYM51010

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 10, Page 2307-2323, May 2026.
Background and purpose Opioids targeting the μ opioid receptor remain largely ineffective in neuropathic pain conditions, emphasizing the need for novel therapeutic strategies. MP135 was reported to reduce thermal nociception in naive animals by activating μ‐δ opioid receptor heteromers.
Perrine Inquimbert   +13 more
wiley   +1 more source

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 9, Page 2123-2138, May 2026.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan   +2 more
wiley   +1 more source

A PK/PD study on antihyperalgesia by an α2/3‐GABAA receptor PAM in mice: Lack of tolerance liability and potential involvement of γ1‐GABAA receptors

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 10, Page 2324-2340, May 2026.
Abstract Background and Purpose GABAA receptors (GABAARs) are heteropentameric ion channels that control almost all CNS functions, including spinal nociception. Most GABAARs contain a γ2 subunit but differ in their α and β subunit composition. TPA023B is an α2/α3 subtype selective, non‐sedative, positive allosteric modulator (PAM) with antihyperalgesic
Elena Neumann   +12 more
wiley   +1 more source

High-Speed Detection of X-ray Pulses Using a Digital Counter Coupled with Perovskite Composite Scintillators. [PDF]

open access: yesACS Appl Mater Interfaces
Khaliq S   +8 more
europepmc   +1 more source

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 10, Page 2518-2532, May 2026.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy